|
1
|
Prostate cancer statistics. World Cancer
Research Fund, London, 2026.
|
|
2
|
Sathishkumar K, Chaturvedi M, Das P,
Stephen S and Mathur P: Cancer incidence estimates for 2022 &
projection for 2025: Result from National Cancer Registry
Programme, India. Indian J Med Res. 156:598–607. 2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Urabe F, Hatakeyama S, Yanagisawa T,
Narita S, Muramoto K, Katsumi K, Takahashi H, Fukuokaya W, Mori K,
Tashiro K, et al: Clinical significance of PSA dynamics in
castration-sensitive prostate cancer treated with ARSI doublet
therapy: A multicenter study. Urol Oncol. 43:e9–e271.e18.
2025.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fiorica F, Buttigliero C, Grigolato D,
Muraro M, Turco F, Munoz F and Tucci M: Addition of new androgen
receptor pathway inhibitors to docetaxel and androgen deprivation
therapy in metastatic Hormone-sensitive prostate cancer: A
systematic review and metanalysis. Curr Oncol. 29:9511–9524.
2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Schaeffer EM, Srinivas S, Adra N, An Y,
Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, et al: NCCN
Guidelines® Insights: Prostate Cancer, Version 3.2024. JNCCN 22:
April 6, 2024.
|
|
6
|
Advanced Prostate Cancer: AUA/SUO
Guideline-American Urological Association, 2026.
|
|
7
|
Kohjimoto Y, Uemura H, Yoshida M, Hinotsu
S, Takahashi S, Takeuchi T, Suzuki K, Shinmoto H, Tamada T, Inoue
T, et al: Japanese clinical practice guidelines for prostate cancer
2023. Int J Urol. 31:1180–1222. 2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
So AI, Chi K, Danielson B, Fleshner N,
Kinnaird A, Niazi T, Pouliot F, Rendon RA, Shayegan B, Sridhar SS,
et al: 2025 canadian urological Association-canadian Uro-oncology
Group Guideline: Metastatic castration-naive and
castration-sensitive prostate cancer (Update). Can Urol Assoc J.
19:E142–E152. 2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Buhmeida A, Pyrhönen S, Laato M and Collan
Y: Prognostic factors in prostate cancer. Diagn Pathol.
1(4)2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Lowentritt B, Pilon D, Khilfeh I, Rossi C,
Muser E, Kinkead F, Waters D, Ellis L, Lefebvre P and Brown G:
Attainment of early, deep prostate-specific antigen response in
metastatic castration-sensitive prostate cancer: A comparison of
patients initiated on apalutamide or enzalutamide. Urol Oncol.
41:e1–e253.e9. 2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Iacovelli R, Ciccarese C, Caffo O, De
Giorgi U, Basso U, Tucci M, Mosillo C, Maruzzo M, Maines F, Casadei
C, et al: The role of fast and deep PSA response in
castration-sensitive prostate cancer. Anticancer Res. 42:165–172.
2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Naqvi SAA, Riaz IB, Imran M, Bin Zafar MD,
Faisal KS, Bin Riaz Z, Singh P and Bryce AH: Deep prostate-specific
antigen response and overall survival in patients with metastatic
castration-sensitive prostate cancer: A systematic review and
meta-analysis. J Clin Oncol. 41 (6_suppl)(s195)2023.
|
|
13
|
Patel UJ and Caulfield S: Apalutamide for
the treatment of nonmetastatic Castration-resistant prostate
cancer. J Adv Pract Oncol. 10:501–507. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Chi KN, Agarwal N and Bjartell A:
Apalutamide for metastatic, Castration-sensitive prostate cancer. N
Engl J Med. 381:13–24. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chowdhury S, Bjartell A, Agarwal N, Chung
BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS,
Özgüroğlu M, Soto ÁJ, Uemura H, et al: Prostate-specific antigen
(PSA) decline with apalutamide therapy is associated with longer
survival and improved outcomes in individuals with metastatic
prostate cancer: A plain language summary of the TITAN study.
Future Oncol. 20:563–578. 2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Merseburger AS, Agarwal N, Bhaumik A,
Lefresne F, Karsh LI, Pereira de Santana Gomes AJ, Soto ÁJ, Given
RW, Brookman-May SD, Mundle SD, et al: Apalutamide plus androgen
deprivation therapy in clinical subgroups of patients with
metastatic castration-sensitive prostate cancer: A subgroup
analysis of the randomised clinical TITAN study. Eur J Cancer.
193(113290)2023.PubMed/NCBI View Article : Google Scholar
|
|
17
|
López-Abad A, Ramírez Backhaus M, Server
Gómez G, Cao Avellaneda E, Moreno Alarcón C, López Cubillana P,
Yago Giménez P, de Pablos Rodríguez P, Juan Fita MJ, Climent Durán
MÁ, et al: Real-world prostate-specific antigen reduction and
survival outcomes of metastatic hormone-sensitive prostate cancer
patients treated with apalutamide: An observational, retrospective,
and multicentre study. Prostate Int. 12:20–26. 2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tohi Y, Kato T, Kobayashi K, Daizumoto K,
Fukuhara H, Ohira S, Katayama S, Shimizu R, Takamoto A, Nishimura
K, et al: Real-world prostate-specific antigen response and
progression to castration-resistant prostate cancer among men with
metastatic castration-sensitive prostate cancer treated with
apalutamide: A multi-institutional study in the Chu-shikoku Japan
Urological Consortium. Jap J Clin Oncol. 54:167–174.
2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Santoni M, Büttner T, Rescigno P, Fiala O,
Cavasin N, Basso U, Taha T, Massari F, Myint ZW, Formisano L, et
al: Apalutamide in metastatic Castration-sensitive prostate cancer:
Results from the multicenter Real-world ARON-3 study. Eur Urol
Oncol. 8:444–451. 2025.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Encarnación Navarro JA, Morillo Macías V,
Borrás Calbo M, De la Fuente Muñoz I, Lozano Martínez A, García
Martínez V, Fernández Fornos L, Guijarro Roche M, Amr Rey O and
García Gómez R: Multicenter real-world study: 432 patients with
apalutamide in metastatic Hormone-sensitive prostate cancer. Curr
Oncol. 32(119)2025.PubMed/NCBI View Article : Google Scholar
|
|
21
|
López-Abad A, Belmonte M, Ramírez Backhaus
M, Server Gómez G, Cao Avellaneda E, Moreno Alarcón C, López
Cubillana P, Yago Giménez P, de Pablos Rodríguez P, Juan Fita MJ,
et al: Ultralow Prostate-specific antigen (PSA) levels and improved
oncological outcomes in metastatic Hormone-sensitive prostate
cancer (mHSPC) patients treated with apalutamide: A Real-world
multicentre study. J Clin Med. 13(6221)2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lowentritt B, Du S, Rossi C, Kinkead F,
Waters D, Moore B, Lefebvre P, Pilon D and Muser EJ: MP29-14
Prostate-specific antigen response and time-to-castration
resistance among patients with metastatic castration sensitive
prostate cancer initiated on apalutamide, enzalutamide, or
abiraterone acetate. J Urol. 209 (Suppl 4)(E387)2023.
|
|
23
|
Maughan BL, Mundle S, Nematian-Samani M,
Wang S, Du S, Liu Y and Ivan Karsh L: Survival Outcomes of APA as a
Starting treatment: Impact in real-world patients with mCSPC
(OASIS). J Clin Oncol. 42 (Suppl 4)(S65)2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chowdhury S, Bjartell A, Agarwal N, Chung
BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS,
Özgüroğlu M, Juárez Soto Á, Uemura H, et al: Deep, rapid, and
durable prostate-specific antigen decline with apalutamide plus
androgen deprivation therapy is associated with longer survival and
improved clinical outcomes in TITAN patients with metastatic
castration-sensitive prostate cancer. Ann Oncol. 34:477–485.
2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Scher HI, Morris MJ, Stadler WM, Higano C,
Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, et
al: Trial design and objectives for Castration-resistant prostate
cancer: Updated recommendations from the prostate cancer clinical
trials working group 3. J Clin Oncol. 34:1402–1418. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hiroshige T, Suekane H, Tokunaga T, Uegaki
M, Iwashita M, Taura H, Hirano T, Mitani T, Matsuo M and Igawa T:
Prognostic stratification using early Prostate-specific antigen
kinetics in men with metastatic Hormone-sensitive prostate cancer.
Anticancer Res. 45:751–759. 2025.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Bryce AH, Chen YH, Liu G, Carducci MA,
Jarrard DM, Garcia JA, Dreicer R, Hussain M, Eisenberger MA,
Plimack ER, et al: Patterns of cancer progression of metastatic
Hormone-sensitive prostate cancer in the ECOG3805 CHAARTED trial.
Eur Urol Oncol. 3:717–724. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Armstrong AJ, Mottet N, Iguchi T,
Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B,
Shore ND, Gomez-Veiga F, et al: Radiographic progression in the
absence of prostate-specific antigen (PSA) progression in patients
with metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc
analysis of ARCHES. J Clin Oncol. 40 (16_suppl)(s5072)2022.
|
|
29
|
Bryce AH, Alumkal JJ, Armstrong A, Higano
CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J,
Tombal B, et al: Radiographic progression with nonrising PSA in
metastatic castration-resistant prostate cancer: Post hoc analysis
of PREVAIL. Prostate Cancer Prostatic Dis. 20:221–227.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Collette L, Burzykowski T, Carroll KJ,
Newling D, Morris T and Schröder FH: European Organisation for
Research and Treatment of Cancer; Limburgs Universitair Centrum;
AstraZeneca Pharmaceuticals. Is prostate-specific antigen a valid
surrogate end point for survival in hormonally treated patients
with metastatic prostate cancer? Joint research of the European
Organisation for Research and Treatment of Cancer, the Limburgs
Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin
Oncol. 23:6139–6148. 2005.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Maeda H, Takeda K, Urushihara H and
Kurokawa T: Searching for potential surrogate endpoints of overall
survival in clinical trials for patients with prostate cancer.
Cancer Rep (Hoboken). 4(e1334)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lowentritt B, Pilon D, Waters D, Rossi C,
Muser E, Kurteva S, Shah A, Khilfeh I, Du S, Ellis L, et al:
Comparison of prostate-specific antigen response in patients with
metastatic castration-sensitive prostate cancer initiated on
apalutamide or abiraterone acetate: A retrospective cohort study.
Urol Oncol. 41:252.e19–e252.e27. 2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lowentritt B, Bilen MA, Khilfeh I, Rossi
C, Du S, Kinkead F, Diaz L, Pilon D, Ellis L and Shore ND: Overall
survival in patients with metastatic castration-sensitive prostate
cancer treated with apalutamide versus abiraterone acetate: A
head-to-head analysis of real-world patients in the USA. J Comp Eff
Res. 14(e250023)2025.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bilen MA, Lowentritt BH, Burbage S, Joshi
K, Patel C, Rossi C, Kinkead F, Wong G, Pilon D, Shore ND, et al:
Real-world comparison of prostate-specific antigen (PSA) response
among patients with metastatic castration-sensitive prostate cancer
(mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ). JCO
Oncol Pract. 21 (10_suppl)(s570)2025.
|
|
35
|
Lu Y, Jiang J, Yang G, Ding H, Zheng Q, Ji
L, Wang Y, Dong Z, Zhai Z, Tian J, et al: Comparative effectiveness
of multiple androgen receptor signaling inhibitor medicines with
androgen deprivation therapy for metastatic hormone-sensitive
prostate cancer: A study in the real world. Front Oncol.
14(1324181)2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Gao D, Shen Y, Xu L, Sun Y, Hu H, Xu B,
Wang Z and Xu H: Acetate utilization promotes hormone therapy
resistance in prostate cancer through neuroendocrine
differentiation. Drug Resist Updat. 77(101158)2024.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wenes M, Jaccard A, Wyss T,
Maldonado-Pérez N, Teoh ST, Lepez A, Renaud F, Franco F, Waridel P,
Yacoub Maroun C, et al: The mitochondrial pyruvate carrier
regulates memory T cell differentiation and antitumor function.
Cell Metab. 34:731–746.e9. 2022.PubMed/NCBI View Article : Google Scholar
|
